La tunisie Medicale - 2022 ; Vol 100 ( n°04 ) : 335-341
[ Vu 534 fois ]

Aim: To investigate the prognostic value of quality of life (QoL) assessment among Tunisian lung cancer patients for survival.
Methods: A prospective cohort study was performed from January 2018 to June 2019. Performance status (PS), QoL questionnaire-core30 (QLQ-C30), QoL questionnaire-Lung Cancer 13 (QLQ-LC13) and European QoL-5 dimensions-3level version questionnaire (EQ-5D-3L) were used to QoL assessment. Patients were divided into 2 groups according to global QLQ-C30 score, a Clinically Significant Deficit (CSD) was considered if the score was ≤50. Cox regression analysis and Stepwise regression analysis were performed to evaluate the prognostic significance of QoL. Overall survival (OS) was calculated using the Kaplan-Meier method. Log-rank test was used to compare survival curves. p value cutoff for statistical significance was 0.05.
Results: One hundred patients were included. Median OS for patients with CSD in QoL was 365 days, compared with 467 days for those without significant difference in QoL (Log-rank test, p=0.036). Similarly, Median progression free survival for patients with CSD in QoL was 122 days compared with 326 days for those who did not report a significant difference in QoL (Log-rank test, p=0.05). Upon multivariable stepwise regression analysis, Global QoL score (QLQ-C30) was a significant predictor of OS (coefficient estimate (CE)=0.336, p=0.005), along with stage IV (CE=-0.193, p=0.033) and tumor progression (CE =-0.238, p=0.047).
Conclusion: QoL was a predictor of survival in our cohort of patients with lung cancer. This should recommend an active intervention for patients with a significant deficit in QoL in Early Palliative Care.

Mots Clés
  1. Chabowski M, Polanski J, Jankowska-Polańska B, Rosińczuk J, Szymanska-Chabowska A. Quality of life of patients with lung cancer. OncoTargetsTher. 2016 Feb;1023.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
  3. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. In: Ahmad A, Gadgeel S, editors. Lung Cancer and Personalized Medicine [Internet]. Cham: Springer International Publishing; 2016 [cited 2020 Mar 15]. p. 1–19. Available from: http://link.springer. com/10.1007/978-3-319-24223-1_1
  4. Bhattacharya P, Dessain SK, Evans TL. Palliative Care in Lung Cancer: When to Start. CurrOncol Rep. 2018 Nov;20(11):90.
  5. Stinchcombe TE, Socinski MA. Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. Proc Am Thorac Soc. 2009 Apr 15;6(2):233–41.
  6. Tanvetyanon T. Quality-of-Care Indicators for Non-Small Cell Lung Cancer. Cancer Control. 2009 Oct;16(4):335–41.
  7. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J ThoracOncol. 2016 Jan;11(1):39–51.
  8. Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev. 2013 Dec;3(1):15.
  9. Osoba D. Health-related quality of life and cancer clinical trials. TherAdv Med Oncol. 2011 Mar;3(2):57–71.
  10. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009 Dec;7(1):102.
  11. Lemonnier I, Baumann C, Jolly D, Arveux P, Woronoff-Lemsi M-C, Velten M, et al. Solitary pulmonary nodules: consequences for patient quality of life. Qual Life Res. 2011 Feb;20(1):101–9.
  12. Khalladi R, Gargouri I, Zedini C, Saad HB. Qualité de vie des patients Tunisiens atteints de cancer du poumon: étude descriptive Quality of life of Tunisian patients withlung cancer: descriptive study. Tunis Med. 2019;97:13.
  13. Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat M-C, Daurès J-P, et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol. 2008 Aug;19(8):1458–64.
  14. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer. 1982 Jul 15;50(2):326-31.
  15. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, et al. Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006 Nov;17(11):1698–704.
  16. Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, et al. Relationship Between Deficits in Overall Quality of Life and Non–Small-Cell Lung Cancer Survival. J ClinOncol. 2012 May 1;30(13):1498–504.
  17. Khalladi R, Gargouri I, Zedini C, Ben Saad H. Which factors influence the quality of life of Tunisian patients with lung cancer ? J Fac Med Or,2 (9) : 597-608.
  18. Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, et al. Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. Eur J Cancer. 2016 Jan;52:120–8.
  19. Braun DP, Gupta D, Staren ED. Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer. 2011 Dec;11(1):353.
  20. Wood R, Taylor-Stokes G, Smith F, Chaib C. The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden. Qual Life Res. 2019 Jul;28(7):1849–61.
  21. Khan I, Morris S, Pashayan N, Matata B, Bashir Z, Maguirre J. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016 Dec;14(1):60.
  22. Carnio S, Di Stefano R, Novello S. Fatigue in lung cancer patients: symptom burden and management of challenges. Lung Cancer Targets Ther. 2016 May;73.
  23. Cramp F, Byron-Daniel J. Exercise for the management of cancerrelated fatigue in adults. Cochrane Pain, Palliative and Supportive Care Group, editor. Cochrane Database Syst Rev [Internet]. 2012 Nov 14 [cited 2020 Mar 18]; Available from: http://doi.wiley. com/10.1002/14651858.CD006145.pub3
  24. Jones LW. Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer. J Clin Oncol. 2015 Dec10;33(35):4134–7.
Espace membre
E-mail :
Mot passe :
Mémoriser Mot de passe oublié S'inscrire
Enfant traitement Tunisie Chirurgie pronostic diagnostic Maladie de crohn facteurs de risque Cancer du sein Cancer dépistage Mortalité Coelioscopie prévalence obésité
S'inscrire pour recevoir les newsletters
E-mail :
Rejoignez-nous !